787 related articles for article (PubMed ID: 24385407)
1. Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Takahashi S; Mizuno O; Sakaguchi T; Yamada T; Inuyama L
Adv Ther; 2014 Jan; 31(1):118-29. PubMed ID: 24385407
[TBL] [Abstract][Full Text] [Related]
2. Prospective registry of carotid artery stenting in Japan--investigation on device and antiplatelet for carotid artery stenting.
Sakai N; Yamagami H; Matsubara Y; Ezura M; Hyodo A; Matsumaru Y; Miyachi S; Okada Y; Terada T; Yokoi H; Nakamura M; Matsumoto Y; Sakai C;
J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1374-84. PubMed ID: 24534127
[TBL] [Abstract][Full Text] [Related]
3. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
[TBL] [Abstract][Full Text] [Related]
4. Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Alvarez-Sabín J; Quintana M; Santamarina E; Maisterra O
Cerebrovasc Dis; 2014; 37(3):181-7. PubMed ID: 24503927
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
7. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Diener HC
Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Biller J
J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
[TBL] [Abstract][Full Text] [Related]
10. New insights in antiplatelet therapy for patients with ischemic stroke.
Chaturvedi S; Bhattacharya P
Neurologist; 2011 Sep; 17(5):255-62. PubMed ID: 21881467
[TBL] [Abstract][Full Text] [Related]
11. [Antiplatelet therapy: update in secondary stroke prevention].
Uchiyama S
Brain Nerve; 2013 Jul; 65(7):771-82. PubMed ID: 23832980
[TBL] [Abstract][Full Text] [Related]
12. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
14. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.
Dengler R; Diener HC; Schwartz A; Grond M; Schumacher H; Machnig T; Eschenfelder CC; Leonard J; Weissenborn K; Kastrup A; Haberl R;
Lancet Neurol; 2010 Feb; 9(2):159-66. PubMed ID: 20060783
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
Weimar C; Cotton D; Sha N; Sacco RL; Bath PM; Weber R; Diener HC
Cerebrovasc Dis; 2013; 35(6):538-43. PubMed ID: 23816610
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
Hong KS; Kim BJ; Lee JY; Kwon SU;
Int J Stroke; 2015 Oct; 10(7):1153-8. PubMed ID: 26044566
[TBL] [Abstract][Full Text] [Related]
17. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet Therapy After Noncardioembolic Stroke.
Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
[TBL] [Abstract][Full Text] [Related]
19. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Tran H; Anand SS
JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
[TBL] [Abstract][Full Text] [Related]
20. Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Hills NK; Johnston SC
Stroke; 2008 Apr; 39(4):1228-32. PubMed ID: 18323509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
